Oncologic Outcomes of Breast-Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Authors:
- Sandra E. Díaz-CasasSDSandra E. Díaz-Casas
- Flavio J. Rosero-Díazdel CastilloFCFlavio J. Rosero-Díazdel Castillo
- Sara Mendoza-DíazSMSara Mendoza-Díaz
- Andersson Sáenz-LadinoASAndersson Sáenz-Ladino
- Ricardo Sánchez-PedrazaRSRicardo Sánchez-Pedraza
- Sonia P. Silva-CárdenasSSSonia P. Silva-Cárdenas
- Andrea Zuluaga-LiberatoAZAndrea Zuluaga-Liberato
- Ximena Briceño-MoralesXBXimena Briceño-Morales
- Luis Guzmán-AbiSaabLGLuis Guzmán-AbiSaab
- Óscar Gamboa-GarayÓGÓscar Gamboa-Garay
- Javier Ángel-AristizábalJÁJavier Ángel-Aristizábal
- Iván Mariño-LozanoIMIván Mariño-Lozano
Open Access
Abstract
Background: Breast-conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with non-metastatic breast cancer at a referral cancer center in a medium-resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as the initial treatment and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow-up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were a locally advanced clinical stage (HR 5.13; p = 0.01), triple-negative subtype (HR 8.02; p < 0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p < 0.01). Conclusions: Breast-conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. The time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.Keywords
All Related Versions
Funding Information
- Instituto Nacional de Cancerología, Bogotá, Colombia
This publication has 38 references indexed in Scilit:
- Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancerRadiotherapy and Oncology, 2020
- Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancerJournal of Surgical Oncology, 2017
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe Lancet Oncology, 2014
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trialsThe Lancet, 2014
- Oncologic safety of breast‐conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancerJournal of Surgical Oncology, 2013
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trialsThe Lancet, 2011
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 2010
- Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902Breast Cancer Research and Treatment, 2008
- Quadrantectomy versus lumpectomy for small size breast cancerEuropean Journal of Cancer, 1990
- Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancerRadiotherapy and Oncology, 1989